Back to search

Peptide record

TPDB92028

Transportan 10 Antibacterial Anticancer Antifungal Antiparasitic Blood-Brain Barrier Cell-penetrating Peptides Hemolysis Toxicity standard
21 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB92028
Transportan 10
Antibacterial Anticancer Antifungal Antiparasitic Blood-Brain Barrier Cell-penetrating Peptides Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides
AntiBP3 dbAMP Peptipedia Antifungipept CAFPdb dbAMP 3.0 i2APP B3Pred BBPpredict CellPPD CellPPD-MOD CPPsite3.0 PerseuCPP HemoPI Hemolytic2 PD_Hemolysis
standard
No
A 21-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, Peptipedia, and other sources, with an available 3D structural model.
C-terminal: Amide group is attached N-terminal: N-terminal Fmoc group was removed and the propiola
Sequence
AGYLLGKINLKALAALAKKIL
Physicochemical Analysis
C104H184N26O24
RDCEQHMFPSTWV
L
2182.76
10.64
4
0
14
+4
-1.37
0.933
172.38
Mammalian: 4.4 hour Yeast: >20 hour E.coli: >10 hour
1490
68.26
2
Residue Composition
number
5
A
0
R
1
N
0
D
0
C
0
E
0
Q
2
G
0
H
2
I
6
L
4
K
0
M
0
F
0
P
0
S
0
T
0
W
1
Y
0
V
Amino Acid Distribution
A: 5 R: 0 N: 1 D: 0 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 2 L: 6 K: 4 M: 0 F: 0 P: 0 S: 0 T: 0 W: 0 Y: 1 V: 0
Chemical Descriptors
21
C104H184N26O24
2182.76
10.64
+4
-1.37
0.933
Amide group is attached
Linear
N-terminal Fmoc group was removed and the propiola
Similarity
Cationic
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Evidence Records 10 records
Evidence 1 Activity

Activity

Blood-Brain Barrier
1.6 ± 0.9micromolar

Target

S. aureus MRSA N315

Assay & Model

100000 CFU/mL
Origin/Source
60 mg/kg
Fluorescence microscopy assay
It crosses the BBB.
MIC

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Intravenous
It shows intermediate susceptibility.
Alone
Evidence 2 Activity

Activity

Blood-Brain Barrier
1.6 ± 0.8 micromolar

Target

S. aureus MRSA N315

Assay & Model

100000 CFU/mL
Origin/Source
60 mg/kg
Fluorescence microscopy assay
It crosses the BBB.
MIC

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Intravenous
It shows intermediate susceptibility.
Alone
Evidence 3 Activity

Activity

Blood-Brain Barrier
1.6 ± 0.9 micromolar

Target

S. aureus MRSA 12673

Assay & Model

100000 CFU/mL
Origin/Source
60 mg/kg
Fluorescence microscopy assay
It crosses the BBB.
MIC

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Intravenous
It shows intermediate susceptibility.
Combined with Vanomycin
Evidence 4 Activity

Activity

Blood-Brain Barrier
1.6 ± 0.7 micromolar

Target

S. aureus MRSA 12673

Assay & Model

100000 CFU/mL
Origin/Source
60 mg/kg
Fluorescence microscopy assay
It crosses the BBB.
MIC

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Intravenous
It shows intermediate susceptibility.
Combined with Vanomycin
Evidence 5 Activity

Activity

Blood-Brain Barrier
1.6 ± 0.3 micromolar

Target

S. aureus MRSA hetero-VISA 6347b

Assay & Model

100000 CFU/mL
Origin/Source
60 mg/kg
Fluorescence microscopy assay
It crosses the BBB.
MIC

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Intravenous
It shows intermediate susceptibility.
Combined with Vanomycin
Evidence 6 Activity

Activity

Blood-Brain Barrier
3.1 ± 0.8 micromolar

Target

S. aureus MRSA hetero-VISA 6347b

Assay & Model

100000 CFU/mL
Origin/Source
60 mg/kg
Fluorescence microscopy assay
It crosses the BBB.
MIC

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Intravenous
It shows intermediate susceptibility.
Combined with Vanomycin
Evidence 7 Activity

Activity

Blood-Brain Barrier
50.0 ± 10.2 micromolar

Target

Enterococcus faecium 3934825

Assay & Model

Origin/Source
60 mg/kg
Fluorescence microscopy assay
It crosses the BBB.
MIC

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Intravenous
It shows the resistance
Combined with Vanomycin
Evidence 8 Activity

Activity

Blood-Brain Barrier
25.0 ± 5.1 micromolar

Target

Enterococcus faecium 3934825

Assay & Model

Origin/Source
60 mg/kg
Fluorescence microscopy assay
It crosses the BBB.
MIC

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Intravenous
It shows the resistance
Combined with Vanomycin
Evidence 9 Activity

Activity

Blood-Brain Barrier
6.3 ± 1.6 micromolar

Target

Enterococcus faecalis 3937158

Assay & Model

Origin/Source
60 mg/kg
Fluorescence microscopy assay
It crosses the BBB.
MIC

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Intravenous
It shows intermediate susceptibility.
Combined with Vanomycin
Evidence 10 Activity

Activity

Blood-Brain Barrier
25.0 ± 6.5 micromolar

Target

Enterococcus faecalis 3937158

Assay & Model

Origin/Source
60 mg/kg
Fluorescence microscopy assay
It crosses the BBB.
MIC

Source & Reference

NA
B3Pdb

Other

Chemically synthesized
Intravenous
It shows the resistance
Combined with Vanomycin
Additional Detail Fields 1 fields
Intravenous